Arcutis Biotherapeutics Inc ZORYVE (roflumilast) Foam Launch Call Transcript
Good day and welcome to the Arcutis Biotherapeutics ZORYVE foam conference call. (Operator Instructions) As a reminder, today's call is being recorded. I would now turn the conference over to your host, Ms. Latha Vairavan, Arcutis Investor Relations. Please go ahead.
Thank you, Valerie. Good afternoon, everyone and thank you for joining us today to discuss the launch of the ZORYVE topical foam for seborrheic dermatitis. Slides for today's call are available on the Investor section of our website. On the call today, we have Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; John Smither, Chief Financial Officer; and our special guest, Dr. Melinda Gooderham, Medical Director at the SKiN Centre for Dermatology. I would like to remind everyone that we will be making forward-looking statements during this call.
These statements are subject to certain risks and uncertainties and our actual results may differ. We encourage you to review all of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
